MFG
ACAD icon

Merit Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Merit Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$976K Sell
38,559
-440
-1% -$9.68K 0.01% 1088
2026
Q1 		$868K Sell
38,999
-412
-1% -$9.85K 0.01% 1058
2025
Q4 		$1.05M Buy
+39,411
New +$942K 0.01% 932

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Merit Financial Group's ACAD Position: Q2 2026 in Review

Merit Financial Group reduced its Acadia Pharmaceuticals (ACAD) stake by 1.1% in Q2 2026, selling an estimated $9.68K and leaving 38,559 shares worth $976K. The position accounts for 0.01% of the portfolio, ranked #1088.

Merit Financial Group first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.05M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Merit Financial Group held 38,559 shares of Acadia Pharmaceuticals worth $976K as of Q2 2026.
  • Merit Financial Group sold 440 Acadia Pharmaceuticals shares in Q2 2026, an estimated $9.68K.
  • Acadia Pharmaceuticals made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #1088 holding.
  • Merit Financial Group first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Merit Financial Group's Acadia Pharmaceuticals position peaked at $1.05M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.